Literature DB >> 30705849

Interplay between immune cells in lung cancer: beyond T lymphocytes.

Juan-Manuel Hernandez-Martinez1,2, Edgar Vergara1, Edgar Montes-Servín1, Oscar Arrieta1.   

Abstract

Entities:  

Year:  2018        PMID： 30705849      PMCID： PMC6328695          DOI： 10.21037/tlcr.2018.11.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  33 in total

Review 1.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

2.  The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.

Authors:  Audrey L Kinter; Emily J Godbout; Jonathan P McNally; Irini Sereti; Gregg A Roby; Marie A O'Shea; Anthony S Fauci
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

3.  Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Authors:  Christian M Capitini; Terry J Fry; Crystal L Mackall
Journal:  Am J Immunol       Date:  2009-01-01

Review 4.  The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation.

Authors:  Steven A Corfe; Christopher J Paige
Journal:  Semin Immunol       Date:  2012-03-14       Impact factor: 11.130

5.  Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties.

Authors:  Sven Brandau; Sokratis Trellakis; Kirsten Bruderek; Dominik Schmaltz; Gabriele Steller; Motaz Elian; Henrik Suttmann; Marcus Schenck; Jürgen Welling; Peter Zabel; Stephan Lang
Journal:  J Leukoc Biol       Date:  2010-11-24       Impact factor: 4.962

6.  Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

Authors:  B Almand; J I Clark; E Nikitina; J van Beynen; N R English; S C Knight; D P Carbone; D I Gabrilovich
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

7.  Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.

Authors:  Chien-Ying Liu; Yu-Min Wang; Chih-Liang Wang; Po-Hao Feng; How-Wen Ko; Yun-Hen Liu; Yi-Cheng Wu; Yen Chu; Fu-Tsai Chung; Chih-Hsi Kuo; Kang-Yun Lee; Shu-Min Lin; Horng-Chyuan Lin; Chun-Hua Wang; Chih-Teng Yu; Han-Pin Kuo
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

8.  Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.

Authors:  Kei Suzuki; Kyuichi Kadota; Camelia S Sima; Jun-ichi Nitadori; Valerie W Rusch; William D Travis; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

9.  CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.

Authors:  Po-Hao Feng; Kang-Yun Lee; Ya-Ling Chang; Yao-Fei Chan; Lu-Wei Kuo; Ting-Yu Lin; Fu-Tsai Chung; Chih-Shi Kuo; Chih-Teng Yu; Shu-Min Lin; Chun-Hua Wang; Chun-Liang Chou; Chien-Da Huang; Han-Pin Kuo
Journal:  Am J Respir Crit Care Med       Date:  2012-09-06       Impact factor: 21.405

10.  Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.

Authors:  Minu K Srivastava; Jacobus J Bosch; James A Thompson; Bruce R Ksander; Martin J Edelman; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2008-03-06       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.